A phase 1 clinical trial of ALT-P7 in advanced HER2+ breast cancer patients (NCT03281824) is being conducted, and preliminary results show good tolerability at the lowest dose, warranting the development of a phase 2 [130]. The gene discussed is ERBB2; the disease is breast carcinoma.